Forte Biosciences Company Insiders
| FBRX Stock | USD 21.71 1.92 9.70% |
Forte Biosciences' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Forte Biosciences suggests that vertually all insiders are extremely bullish. Forte Biosciences employs about 11 people. The company is managed by 6 executives with a total tenure of roughly 26 years, averaging almost 4.0 years of service per executive, having 1.83 employees per reported executive.
Forte Biosciences' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-11-21 | Antony A Riley | Acquired 22514 @ 5.55 | View | ||
| 2023-12-18 | Paul A Wagner | Acquired 10000 @ 0.75 | View | ||
| 2023-12-13 | Paul A Wagner | Acquired 10520 @ 0.7 | View | ||
| 2023-12-11 | Paul A Wagner | Acquired 25000 @ 0.65 | View | ||
| 2023-12-07 | Paul A Wagner | Acquired 36203 @ 0.58 | View |
Monitoring Forte Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Forte |
Forte Biosciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Forte Biosciences' future performance. Based on our forecasts, it is anticipated that Forte will maintain a workforce of slightly above 70 employees by January 2025.Forte Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.8125) % which means that it has lost $0.8125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7091) %, meaning that it created substantial loss on money invested by shareholders. Forte Biosciences' management efficiency ratios could be used to measure how well Forte Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.85 in 2024. Return On Capital Employed is likely to rise to -0.87 in 2024. At this time, Forte Biosciences' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 831.9 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 620.4 K in 2024.Common Stock Shares Outstanding is likely to drop to about 862 K in 2024. Net Loss is likely to drop to about (16.8 M) in 2024
Forte Biosciences Workforce Comparison
Forte Biosciences is rated # 4 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 251. Forte Biosciences holds roughly 11.0 in number of employees claiming about 4% of equities under Health Care industry.
Forte Biosciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Forte Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Forte Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Forte Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 0.75 | 3 | 4 | 24,139 | 1,856 |
| 2024-09-01 | 2.75 | 11 | 4 | 394,625 | 46,423 |
| 2024-06-01 | 0.5 | 2 | 4 | 40,625 | 46,423 |
| 2024-03-01 | 1.0 | 6 | 6 | 1,673,125 | 59,148 |
| 2023-12-01 | 2.3333 | 14 | 6 | 166,990 | 56,412 |
| 2023-09-01 | 2.6667 | 16 | 6 | 1,000,348 | 56,412 |
| 2023-06-01 | 0.5 | 3 | 6 | 48,125 | 65,005 |
| 2022-06-01 | 6.5 | 13 | 2 | 600,000 | 80,000 |
| 2021-03-01 | 1.0 | 1 | 1 | 500.00 | 500.00 |
| 2020-06-01 | 1.25 | 10 | 8 | 284,859 | 458,545 |
| 2017-06-01 | 0.963 | 26 | 27 | 1,012,707 | 1,182,400 |
Forte Biosciences Notable Stakeholders
A Forte Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Forte Biosciences often face trade-offs trying to please all of them. Forte Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Forte Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Paul Wagner | President CEO | Profile | |
| Hubert MD | President Officer | Profile | |
| Barbara MD | Chief Director | Profile | |
| Antony CPA | Chief Officer | Profile | |
| Steven Ruhl | Chief Officer | Profile | |
| Christopher Roenfeldt | Chief Officer | Profile |
About Forte Biosciences Management Performance
The success or failure of an entity such as Forte Biosciences often depends on how effective the management is. Forte Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Forte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Forte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.81) | (0.85) | |
| Return On Capital Employed | (0.92) | (0.87) | |
| Return On Assets | (0.81) | (0.85) | |
| Return On Equity | (0.89) | (0.94) |
Please note, the imprecision that can be found in Forte Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Forte Biosciences. Check Forte Biosciences' Beneish M Score to see the likelihood of Forte Biosciences' management manipulating its earnings.
Forte Biosciences Workforce Analysis
Traditionally, organizations such as Forte Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Forte Biosciences within its industry.Forte Biosciences Manpower Efficiency
Return on Forte Biosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.9M | |
| Net Loss Per Executive | 5.2M | |
| Working Capital Per Employee | 3.2M | |
| Working Capital Per Executive | 5.8M |
Additional Tools for Forte Stock Analysis
When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.